{
    "clinical_study": {
        "@rank": "30250", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "HS-25 5 MG", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "HS-25 10 MG", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "HS-25 20 MG", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "HS-25 30 MG", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "To determine the efficacy of HS-25 (5, 10, 20 or 30 mg) in reducing low density\n      lipoprotein-cholesterol (LDL-C) levels after a 4-week period of treatment in adults with\n      primary hypercholesterolemia."
        }, 
        "brief_title": "A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Primary Hypercholesterolemia", 
        "condition_browse": {
            "mesh_term": "Hypercholesterolemia"
        }, 
        "detailed_description": {
            "textblock": "This is a 4-week, randomized, double-blind, placebo-controlled study designed to assess the\n      effects of the cholesterol absorption inhibitor HS-25 on LDL-C levels in adults who have\n      untreated LDL-C levels ranging from 130-189 mg/dL and fasting triglyceride levels < 350\n      mg/dL.  Eligibility is restricted to 18-65 year old men or women who are using a highly\n      effective birth control method or are not of childbearing potential.  Patients with\n      diabetes, a history of myocardial infarction or other clinical evidence of atherosclerotic\n      vascular disease are not eligible for participation in the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men, or women using a highly effective birth control method or not of child-bearing\n             potential, who are 18 to 65 years of age at Visit 1 (screening visit).\n\n          -  LDL-C 130 to 189 mg/dL (inclusive) on a cholesterol lowering diet but no lipid\n             modifying drug treatment for at least 6 weeks. A qualifying LDL-C value must be\n             obtained at the beginning and end of the placebo run-in (Visit 2 and Visit 3) and the\n             Visit 3 value must be within 15% of the value at Visit 2, higher or lower; the\n             average of both qualifying values must be in the range of 130 to 189 mg/dL\n             (inclusive) for inclusion in the study.\n\n          -  TG \u2264 350 mg/dL on a cholesterol lowering diet but no lipid modifying drug treatment\n             for at least 6 weeks and TG levels must be \u2264 350 mg/dL at both Visit 2 and Visit 3\n\n          -  Compliance of 80% to 120% with assigned study drug regimen during a 2 week placebo\n             run-in phase.\n\n        Exclusion Criteria:\n\n          -  Women who are pregnant or breast feeding.\n\n          -  History of stroke, myocardial infarction, unstable angina, heart failure or any\n             arterial revascularization procedure (eg, carotid, coronary, aorta, peripheral\n             arterial).\n\n          -  History of diabetes or glycosylated hemoglobin (HbA1c) > 6.5.\n\n          -  History of moderate to severe lactose intolerance (eg, unable to drink a glass of\n             milk).\n\n          -  History of hospitalization for treatment of a major psychiatric disorder.\n\n          -  History of drug or alcohol abuse as defined by the Diagnostic and Statistical Manual\n             (DSM-5) within the prior 12 months.\n\n          -  History of regular alcohol consumption exceeding 7 drinks/week for females or 14\n             drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of\n             hard liquor) within 6 months prior to screening.\n\n          -  Hospitalization for a duration > 24 hours for any reason within the prior 3 months\n             that, in the opinion of the investigator, may affect adherence to study procedures.\n\n          -  History of a positive test for human immunodeficiency virus, hepatitis B or hepatitis\n             C.\n\n          -  History of cancer with the exception of well-treated basal cell or squamous cell\n             carcinoma of skin, or in-situ cervical carcinoma.\n\n          -  Presence of any condition which, in the opinion of the investigator, is likely to\n             compromise completion of this trial or not be in the best interest of the subject.\n\n          -  History of intolerance to ezetimibe.\n\n          -  Participation in a prior study of HS 25.\n\n          -  Participation in a study of an investigational drug or device within the prior 3\n             months unless subject has documentation of placebo administration in a\n             placebo-controlled drug treatment trial only.\n\n          -  Treatment with a fibric acid derivative (eg, fenofibrate, gemfibrozil), probucol,\n             warfarin, systemic corticosteroid, cyclosporine or other immunosuppressant agent\n             within the prior 12 weeks.\n\n          -  Anticipated need or frequent use of acetaminophen (> 2 gm/day, that is required >\n             4x/week).\n\n          -  Vitamins, herbal and dietary supplements must be discontinued at screening unless\n             subject has been on a long-term daily regimen and agrees to continue this regimen\n             during the study.\n\n          -  Alanine aminotransferase (ALT) > 1.0 \u00d7 upper limit of normal (ULN) at Visit 1, Visit\n             2 or Visit 3.\n\n          -  Aspartate aminotransferase (AST) > 1.0 \u00d7 ULN at Visit 1, Visit 2 or Visit 3.\n\n          -  Unexplained (not due to exercise or strenuous activity) creatinine kinase increase >\n             2 \u00d7 ULN at Visit 1, Visit 2 or Visit 3.\n\n          -  Estimated glomerular filtration rate (Modification of Diet in Renal Disease) < 60\n             mL/min/1.73m2 at Visit 1, Visit 2 or Visit 3.\n\n          -  Thyroid stimulating hormone outside of the normal range.\n\n          -  Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for\n             treatment of either a psychiatric or physical disease (eg, infectious disease) must\n             not be enrolled.\n\n          -  Any other laboratory abnormality considered by the investigator to be clinically\n             significant.\n\n          -  Any subject with an electrocardiogram (ECG) having a QTc interval \u2265 450 msec, or any\n             other abnormality considered by the investigator to be clinically significant at the\n             end of placebo run-in (Visit 3) should not be enrolled."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "360", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02087917", 
            "org_study_id": "HS-25-III"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "HS-25 5 MG", 
                    "HS-25 10 MG", 
                    "HS-25 20 MG", 
                    "HS-25 30 MG"
                ], 
                "description": "Assigned study drug (HS-25 or placebo) is to be administered orally once daily in the morning with or without food. Treatment duration 4 weeks.", 
                "intervention_name": "HS-25", 
                "intervention_type": "Drug", 
                "other_name": "HS-25"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Assigned study drug (HS-25 or placebo) is to be administered orally once daily in the morning with or without food. Treatment duration 4 weeks.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "hypercholesterolemia", 
            "cholesterol absorption inhibitor", 
            "placebo-controlled trial"
        ], 
        "lastchanged_date": "May 20, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chandler", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85224"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "West Hills", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Doral", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "South Miami", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Evansville", 
                        "country": "United States", 
                        "state": "Indiana"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Overland Park", 
                        "country": "United States", 
                        "state": "Kansas"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Auburn", 
                        "country": "United States", 
                        "state": "Maine"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bethesda", 
                        "country": "United States", 
                        "state": "Maryland"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Methuen", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Trenton", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tulsa", 
                        "country": "United States", 
                        "state": "Oklahoma"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Penndel", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greensboro", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norfolk", 
                        "country": "United States", 
                        "state": "Virginia"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia", 
        "overall_official": {
            "affiliation": "Zhejiang Hisun Pharmaceuticals Co., Ltd", 
            "last_name": "Kevin Liao, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percent change from baseline in LDL-C after 4 weeks of double-blind treatment", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02087917"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of participants with reported adverse events during a 4-week period of treatment as a measure of safety and tolerability of HS-25", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Percent change from baseline in LDL-C after a 1 and 2-week period of double-blind treatment", 
                "safety_issue": "No", 
                "time_frame": "1- and 2-weeks"
            }, 
            {
                "measure": "Percent change from baseline in apoprotein B, non-high density lipoprotein-cholesterol, total cholesterol, triglycerides, high density lipoprotein-cholesterol and apoprotein A1 levels after a 1, 2 and 4-week period of treatment", 
                "safety_issue": "No", 
                "time_frame": "1-, 2- and 4-week periods"
            }, 
            {
                "measure": "Mean concentration of HS-25 dose and its major metabolite (HS-25-M1) during treatment with HS-25 5, 10, 20 or 30 mg.", 
                "safety_issue": "No", 
                "time_frame": "1-, 2- and 4-week"
            }, 
            {
                "measure": "Correlation between trough HS-25 and HS-25-M1 levels and percent change in LDL-C, apoA1, apoB, non-HDL-C, TC, TG, and HDL-C during a 4-week period of HS-25 treatment.", 
                "safety_issue": "No", 
                "time_frame": "1-, 2- and 4-week"
            }
        ], 
        "source": "Zhejiang Hisun Pharmaceutical Co. Ltd.", 
        "sponsors": {
            "collaborator": {
                "agency": "Covance", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Zhejiang Hisun Pharmaceutical Co. Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}